Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Dr Camidge on novel NSCLC agents: we want to see the duration of benefit

Ross Camidge • 28 Sep 2019
ESMO 2019
General Lung Cancer Non-Small Cell Lung Cancer Sotorasib

Ross Camidge, MD, PhD, University of Colorado, Denver, CO, gives his thoughts on the new data in lung cancer – highlighting the need to see a duration of benefit. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Ross Camidge

3:21
Hot topics in 2020: lung cancer
Ross Camidge • 26 Mar 2020
4:15
COVID-19 & treating patients with lung cancer
Ross Camidge • 26 Mar 2020
10:43
Updates in ALK+ NSCLC
Ross Camidge • 26 Mar 2020
1:30
Efficacy of lorlatinib in NSCLC post-second generation ALK TKI
Ross Camidge • 28 Sep 2019

Related Videos

2:45
Assessing operability in NSCLC: challenges and considerations
Mariana Brandao • 18 Apr 2024
2:03
Biomarker detection for early cancer detection
Robert Rintoul • 19 Apr 2024
1:47
Assessing follow-up strategies in post-surgical lung cancer: insights from a Phase III trial
Robert Rintoul • 19 Apr 2024
7:37
What is the optimal follow-up for lung cancer long term survivors?
Robert Rintoul • 19 Apr 2024
The content of VJOncology is intended for healthcare professionals